bioMerieux SA
BIM
ISIN FR0013280286 / Valor 38147803
bioMerieux SA
UMushroom community rating:
About company
bioMérieux SA is a global leader in the field of in vitro diagnostics, providing a wide range of diagnostic solutions to healthcare providers. The company specializes in the development, production, and marketing of diagnostic systems and services that are used in clinical applications. Among its innovative offerings, bioMérieux provides the VIDAS® KUBE™, an advanced automated immunoassay solution that enhances laboratory operations with its flexibility and cost-effectiveness. Additionally, the company offers SPOTFIRE®, a multiplex PCR solution tailored for point-of-care testing that delivers rapid, onsite actionable results, and VITEK® MS PRIME, which leverages mass spectrometry technology to improve daily laboratory workflows and patient care, particularly in the critical area of sepsis management. bioMérieux's commitment to advancing healthcare is evident in its comprehensive approach to sepsis management, offering solutions that support the entire process from antibiotic initiation through to appropriate discontinuation. Through its focus on innovation and efficiency, bioMérieux SA plays a crucial role in enhancing diagnostic capabilities and improving patient outcomes worldwide.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (14.08.2024):
Income
bioMérieux SA reported a contributive operating income of €610 million for the fourth quarter of 2023, representing 16.6% of sales. This marks a 2% increase at constant exchange rates and scope, despite facing higher-than-expected negative forex exchange headwinds amounting to -€55 million.
Operating Income
The Group's operating income for the fourth quarter of 2023 was €439 million, a decrease of 25% compared to €587 million in 2022. This decline was primarily due to the amortization and impairment of acquisition-related intangible assets, which amounted to €171 million, up from €77 million in 2022.
Net Income
bioMérieux SA's net income, Group share, reached €358 million in the fourth quarter of 2023, down from €452 million in 2022. The effective tax rate for the period stood at 26.2%, compared to 24.1% in 2022, mainly due to the impact of the Hybiome impairment.
Cash Management
Free cash flow for bioMérieux SA in the fourth quarter of 2023 was €115 million, down from €195 million in 2022. This decrease was influenced by a rise in working capital requirements, primarily due to an increase in inventories by €193 million, and capital expenditures amounting to €338 million, up from €287 million in 2022.
Dividend
The Board of Directors of bioMérieux SA recommended a stable dividend of €0.85 per share for the fourth quarter of 2023, representing a payout ratio of 28% of net income, Group share. This recommendation will be presented for approval at the Annual General Meeting on May 23, 2024.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
12099 M
Market cap (USD)
84,702
Daily traded volume (Shares)
97.7 / 96
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
